Cheng Tzu Yen

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations

Rafael Caparica, Cheng Tzu Yen, Renata A. Coudry et al. · Journal of Thoracic Oncology · 2016 · 63 citations

Medicine, Genetics, Oncology +12

Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors

Alberto Julius Alves Wainstein, Aknar Calabrich, Andréia Cristina de Melo et al. · 2017 · 24 citations

Life Sciences, Immunology, Oncology +16

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Licitra, Kevin J. Harrington et al. · Clinical Cancer Research · 2025 · 19 citations · Full text

Medicine, Oncology, Pharmacology +16